Viropro Inc 最大收入来源是 Subscription Solutions,在最近的收益报告中收入为 247,870,000。就地区而言, United States 是 Viropro Inc 的主要市场,收入为 253,484,000。
Viropro Inc 是否盈利?
不,根据最新的财务报表,Viropro Inc 的净损失为 $-1
Viropro Inc 有负债吗?
不,Viropro Inc 的负债为 0
Viropro Inc 的流通股有多少?
Viropro Inc 的总流通股为 313.47
关键数据
前收盘价
$0
开盘价
$0
当日区间
$0 - $0
52周范围
$0 - $0.0001
交易量
75.0K
平均成交量
0
股息收益率
--
每股收益(TTM)
-0.00
市值
$23.4K
什么是 VPRO?
Viropro, Inc. engages in the development, manufacture and sale of biopharmaceutical products. The company is headquartered in Irvine, California and currently employs 34 full-time employees. The company went IPO on 2001-06-21. The firm conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The firm intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.